That puts pressure on the biotech and pharmaceutical companies that make the drugs, putting them in a position where they have less leverage when negotiating how the drug will get paid for. To counter that, biotech and pharma will have to do big deals of their own, Goldman Sachs analysts wrote…
News
- Big pharma's under increasing pressure, and now everyone's just waiting for a 'detonator' to set off ...
- US stocks end mostly lower as midday gains slip away
Arcus Biosciences Founder and CEO Terry Rosen, right, is applauded as he rings a ceremonial bell when his company's IPO begins trading on the floor of the New York Stock Exchange, Thursday, March 15, 2018. Arcus Biosciences Founder and CEO Terry Rosen, right, is applauded as he rings a…
- Worldwide study triples number of known genetic risk factors for stroke
UT Health's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced more than 33,000 alumni who are advancing their fields throughout the world. With seven campuses in San Antonio and Laredo, UT Health San Antonio has a FY 2018 revenue…
- Local students go on to state, international science fairs
All of them qualified to go to the Texas Science & Engineer Fair, set for March 23 and March 24 in San Antonio. Top winners move on to the Intel International ... 2nd place; Biomedical and Health Sciences; Raj Sukumar; Trinity School (Junior Division), Midland. Which Vitamin Has The Most…
- Calithera Biosciences' (CALA) CEO Susan Molineaux on Q4 2017 Results - Earnings Call Transcript
Good day, ladies and gentlemen and welcome to the Q4, 2017 Calithera Biosciences Earnings Conference Call. [Operator ... of CB-839 in combination with nivolumab at the SITC meeting, as well as the presentation of CB-839 in combination with paclitaxel at the San Antonio Breast Cancer Symposium.…